Human Neutrophil Peptide-1 (HNP-1) has broad-spectrum activity against bacteria and viruses and shows promise as an alternative to traditional antibiotics, though mass production and mechanism understanding remain challenges.
Kills without resistanceUnlike traditional antibiotics, HNP-1 combats bacteria through membrane disruption, making it extremely difficult for pathogens to develop resistance — a critical advantage in the antibiotic resistance crisis.
What the researchers found
HNP-1, produced primarily by human neutrophils, exhibits broad-spectrum antimicrobial activity against both bacteria and viruses. The review identified several key aspects:
• HNP-1 combats pathogens without leading to the resistance patterns seen with traditional antibiotics
• The peptide has multiple functions beyond direct antimicrobial killing, including immune regulatory roles
• Mass production has been a major barrier to clinical use — microbial biosynthesis systems offer a cost-effective alternative to human extraction
• Recent studies have revealed HNP-1's endogenous bactericidal mechanism, advancing understanding of how it kills pathogens
• The peptide's gene expression, distribution, and regulatory elements controlling its production are now better understood
Why it matters
Antibiotic resistance is one of the biggest threats to global health, with drug-resistant infections killing over a million people annually. HNP-1 represents a fundamentally different approach — using the body's own antimicrobial peptide as a therapeutic agent. Because HNP-1 kills bacteria by disrupting their membranes (rather than targeting specific proteins like antibiotics do), bacteria have much more difficulty developing resistance. If production challenges can be solved, HNP-1 could become a powerful weapon against drug-resistant infections.
How the study worked
This was a comprehensive narrative review examining published literature on HNP-1, covering its molecular structure, gene expression, tissue distribution, immune functions, antimicrobial mechanisms, biosynthesis methods, and potential clinical applications. The review integrated studies on both the basic biology of HNP-1 and applied research on production methods.
What this study cannot tell us
This is a narrative review that summarizes existing knowledge rather than presenting new data. The clinical application of HNP-1 remains theoretical — no human clinical trials are reported. The mass production challenge, while being addressed through microbial biosynthesis, has not been fully solved. The review may not cover all recent studies comprehensively. Additionally, antimicrobial peptides can have off-target effects (e.g., toxicity to host cells at high concentrations) that are not deeply explored.
How to read the evidence
This is a narrative review synthesizing the current state of knowledge on HNP-1. While comprehensive, it does not present original experimental data or apply systematic review methodology. It maps the field rather than testing specific hypotheses.
When this study was published
Published in 2025, this is a current review capturing the latest understanding of HNP-1 biology and recent advances in microbial biosynthesis methods for production.
The bigger picture
HNP-1 is part of the alpha-defensin family — one of the first lines of immune defense in the human body. The growing interest in developing antimicrobial peptides as alternatives to antibiotics has put HNP-1 in the spotlight. This review captures a field at a turning point: the biology of HNP-1 is increasingly understood, and production technology is catching up. Combined with the urgent need for new antimicrobial agents, HNP-1 is positioned as a leading candidate among human-derived antimicrobial peptides for clinical development.
Questions still open
- Can microbial biosynthesis produce HNP-1 at sufficient scale and purity for clinical use?
- Would systemically administered HNP-1 be safe, or would it need to be restricted to topical or localized applications?
- How does HNP-1's antimicrobial potency compare to other defensins and synthetic antimicrobial peptides in head-to-head studies?
Common questions
What is HNP-1 and where does it come from?
Why can't bacteria develop resistance to HNP-1 like they do with antibiotics?
Read the original research
HNP-1: From Structure to Application Thanks to Multifaceted Functions.
Microorganisms, 13(2)
Citation
Zhang, Jiaqi; Liu, Zhaoke; Zhou, Zhihao; Huang, Zile; Yang, Yifan; Wu, Junzhu; Liu, Yanhong. (2025). HNP-1: From Structure to Application Thanks to Multifaceted Functions.. Microorganisms, 13(2). https://doi.org/10.3390/microorganisms13020458